Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder

Rhea-AI Summary

Supernus Pharmaceuticals (Nasdaq: SUPN) has announced a webcast and conference call scheduled for Thursday, October 17, 2024, at 4:30 p.m. ET. The purpose of this event is to review data from the open-label Phase 2a study of SPN-820, a treatment for major depressive disorder. The company, which focuses on developing and commercializing products for central nervous system (CNS) diseases, will provide a live webcast with presentation slides accessible via a specific link or through the Events & Presentations section of their Investor Relations website.

Following management's prepared remarks and discussion of the interim trial results, there will be a Q&A session. Participants can pre-register for the call and will receive a personalized dial-in number. A replay of the call will be available on the company's website, with the webcast remaining accessible for 60 days after the live call.

Positive

• Supernus Pharmaceuticals is progressing with Phase 2a study of SPN-820 for major depressive disorder
• The company is demonstrating transparency by hosting a webcast to review study data with investors

Negative

• None.

ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company will hold a webcast and conference call on Thursday, October 17, 2024, at 4:30 p.m. ET to review data from the open-label Phase 2a study of SPN-820 for the treatment of major depressive disorder.

A live webcast with presentation slides will be available via this webcast link or in the Events & Presentations section of the Company’s Investor Relations website at www.supernus.com/investors. Following management’s prepared remarks and discussion of the interim trial results, the call will open for questions.

Participants may also pre-register any time before the call here. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.

Following the live call, a replay will be available on the Company's Investor Relations website at www.supernus.com/investors. The webcast will be available on the Company’s website for 60 days following the live call.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease (PD), cervical dystonia, chronic sialorrhea, and dyskinesia in PD patients receiving levodopa-based therapy. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.

For more information, please visit www.supernus.com.

Forward Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company’s ability to sustain and increase its profitability; the Company’s ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company’s corporate strategy; the Company’s future financial performance and projected expenditures; the Company’s ability to increase the number of prescriptions written for each of its products and the products of its subsidiaries; the Company’s ability to increase its net revenue from its products and the products of its subsidiaries; the Company’s ability to commercialize its products and the products of its subsidiaries; the Company’s ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company’s product research and development activities, including the timing and progress of the Company’s clinical trials, and projected expenditures; the Company’s ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company’s product candidates; the Company’s ability to protect its intellectual property and the intellectual property of its subsidiaries and operate its business without infringing upon the intellectual property rights of others; the Company’s expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company’s product candidates; the accuracy of the Company’s estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company’s ability to increase its manufacturing capabilities for its products and product candidates; the Company’s projected markets and growth in markets; the Company’s product formulations and patient needs and potential funding sources; the Company’s staffing needs; and other risk factors set forth from time to time in the Company’s filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.

CONTACTS:

Jack A. Khattar, President and CEO

Timothy C. Dec, Senior Vice President and CFO

Supernus Pharmaceuticals, Inc.

(301) 838-2591

or

INVESTOR CONTACT:

Peter Vozzo

ICR Westwicke

(443) 213-0505

peter.vozzo@westwicke.com

FAQ

When is Supernus Pharmaceuticals (SUPN) hosting the webcast for SPN-820 Phase 2a study results?

Supernus Pharmaceuticals (SUPN) is hosting the webcast on Thursday, October 17, 2024, at 4:30 p.m. ET to review data from the open-label Phase 2a study of SPN-820 for the treatment of major depressive disorder.

What is the purpose of Supernus Pharmaceuticals' (SUPN) upcoming webcast?

The purpose of the webcast is to review data from the open-label Phase 2a study of SPN-820, Supernus Pharmaceuticals' treatment for major depressive disorder.

How can investors access Supernus Pharmaceuticals' (SUPN) webcast on SPN-820 study results?

Investors can access the webcast through a specific link provided by the company or via the Events & Presentations section of Supernus Pharmaceuticals' Investor Relations website at www.supernus.com/investors.

What type of study is Supernus Pharmaceuticals (SUPN) conducting for SPN-820?

Supernus Pharmaceuticals (SUPN) is conducting an open-label Phase 2a study of SPN-820 for the treatment of major depressive disorder.